PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 133 | 204-215
Article title

The small neuroendocrine intestine tumor as the cause of acute gastrointestinal obstruction and diffuse peritonitis – case report

Content
Title variants
Languages of publication
EN
Abstracts
EN
NET is a group of mostly malignant neoplasms with neuroendocrine differentiation. NET tumors are usually located in the small bowel (sbNET), in most cases their symptoms are the non-specific and surgical treatment of this pathogenic lesions is usually planned. Currently used classification of this group of tumors was created World Health Organization and is based on the rank expression of the Ki-67 (the mitotic index), angioinvasion and size of the tumor. GEP-NETs (gastroenteropancreatic neuroendocrine tumors) are known for expressing specific extracellular markers, such as synaptophysin and chromogranin A (CgA), which are used in a diagnostic process and can be detected with immunohistochemistry methods. The occurrence of clinical symptoms only at the advanced stage of the tumor development explains a low rate of life expectancy. At present, surgical removal of the tumor is the most effective treatment method. This case report describes a 67-year-old female with acute symptoms of gastrointestinal obstruction, complicated with acute peritonitis, who was diagnosed with sbNET during an ad hoc treatment.
Keywords
Discipline
Year
Volume
133
Pages
204-215
Physical description
Contributors
  • SHS in Katowice, Department of Surgical Nurisng and Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40-055 Katowice, Poland
  • SHS in Katowice, Department of Surgical Nurisng and Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40-055 Katowice, Poland
  • SHS in Katowice, Department of Surgical Nurisng and Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40-055 Katowice, Poland
  • SHS in Katowice, Department of Surgical Nurisng and Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40-055 Katowice, Poland
  • SHS in Katowice, Department of Surgical Nurisng and Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40-055 Katowice, Poland
References
  • [1] Ito T, Lee L, Jensen RT. Treatment of Symptomatic Neuroendocrine Tumor Syndromes: Recent Advances and Controversies. Expert opinion on pharmacotherapy 2016; 17(16): 2191-2205
  • [2] Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063-72
  • [3] Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005; 19: 675–697.
  • [4] Kos-Kudła B, Zemczak A. Contemporary methods of diagnosis and treatment of neuroendocrine gastrointestinal tumors. Endokrynologia Polska / Polish Journal of Endocrinology. 2016; 57(2): 174-186.
  • [5] Hubalewska-Dydejczyk A, Stefańska A. Treatment of patients with gastrointestinal neuroendocrine tumors. Medycyna Praktyczna-Chirurgia 2012; 04: 72-84.
  • [6] Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. The Oncologist. 2016; 21(10): 1191-1199.
  • [7] Rindi G, Inzani F, Solcia E.Pathology of gastrointestinal disorders. Endocrinol Metab Clin North Am. 2010 Dec; 39(4): 713-27.
  • [8] Howe JR, Cardona K, Fraker DL, et al., The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society (NANETS). Pancreas. 2017; 46(6): 715-731.
  • [9] Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063-72.
  • [10] Wang YZ, Carrasquillo JP, McCord E, Vidrine R, Lobo ML, Zamin SA, Boudreaux P, Woltering E. Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery. Surgery 2014; 56(6):1498-502.
  • [11] Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH. Liver Metastases of Small Intestine Neuroendocrine Tumors: Ki67 heterogeneity and WHO grade discordance with primary tumors. American journal of clinical pathology 2015; 143(3); 398-404.
  • [12] Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009; 40(9): 1262-8.
  • [13] Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005; 54(4).
  • [14] Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
  • [15] Kaltsas G, Caplin M, Davies P et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017; 5(3): 245-254.
  • [16] Wysocka J, Wysocki W, Kruszyna T. Neuroendocrine neoplasms of the gastrointestinal tract. TNM classification. An editorial based on the update of the TNM classification from 2010. Med Prakt Chir. 2011; 4: 92-96.
  • [17] Bowden M, Zhou CW, Zhang S, Brais L, Rossi A, Naudin L, Thiagalingam A, Sicinska E, Kulke MH. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget. 2017; 8(33): 54331-54344.
  • [18] Illet EE, Langer SW, IH. Olsen, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics. 2015; 5(2): 119-176.
  • [19] Watson GA, Ahmed Y, Picardo S, Chew S, Cobbe S, Mahony C, Crotty J, Wallis F, Shelly MJ, Kiely P, Ipadeola OB, Healy V, Osman N, Gupta RK. Unusual Sites of High-Grade Neuroendocrine Carcinomas: A Case Series and Review of the Literature. The American Journal of Case Reports 2018; 19: 710-723.
  • [20] Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol. 2016; 7(1): 117–124.
  • [21] Bornstein-Quevedo L & Gamboa-Dominguez A. Carcinoid tumors of the duodenum and ampulla of Vater: a clinicomorphologic, immunohistochemical, and cell kinetic comparison. Hum Pathol 2001; 32: 1252–1256.
  • [22] Stamm B, Hedinger CE, Saremaslani P. Duodenalandampullarycarcinoidtumors. A report of 12 cases with pathological characteristics, polypeptide content and relation to MEN 1 syndrome and von Recklinghausen’s disease (neurofibromatosis). Virchows Arch A Pathol Anat Histopathol 1986; 408: 475–489.
  • [23] Holzheimer RG, Mannick JA. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt; 2001.
  • [24] Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System. France: International Agency for Research on cancer (IARC), Lyon 2010. IARS, 2010: S1-S14
  • [25] Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med. 2013; 1(1): 6.
  • [26] Antoniadou F, Korkolis D, Koufopoulos N, Manatakis D, Sakellariou S. A well differentiated neuroendocrine tumor of the jejunum with peritoneal carcinomatosis: A case report. Mol Clin Oncol. 2018; 9(6): 651–655
  • [27] Mantzoros I, Savvala NA, Ioannidis O, Parpoudi S, Loutzidou L, Kyriakidou D, Cheva A, Intzos V, Tsalis K. Midgut neuroendocrine tumor presenting with acute intestinal ischemia. World J Gastroenterol. 2017; 23(45): 8090–8096.
  • [28] Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74–87
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-252fa96b-e8ce-407b-8f70-e1155ca94785
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.